Japanese researchers identify a protein linked to the exacerbation of COPD

Researchers from the RIKEN Advanced Science Institute and Nippon Medical School in Japan have identified a protein likely to be involved in the exacerbation of chronic obstructive pulmonary disease (COPD). This protein, Siglec-14, could serve as a potential new target for the treatment of COPD exacerbation.

In a study published today in the journal Cellular and Molecular Life Sciences the researchers show that COPD patients who do not express Siglec-14, a glycan-recognition , are less susceptible to exacerbation compared with those who do.

COPD is a chronic condition in which the airways and in the lungs become damaged, making it increasingly difficult for air to pass in and out. It is the 4th leading cause of death worldwide and its prevalence is on the rise. Exacerbation, or a sudden worsening of the COPD symptoms often triggered by bacterial or viral infection, directly leads to the decline of the quality of life, and even to the death, of the patient.

Based on the facts that Siglec-14, which is made by innate , binds to the bacteria that often trigger exacerbation, and that approximately 1 out of 4 people in Japan cannot make Siglec-14 because of genetic polymorphism, the research team led by Drs. Takashi Angata and Naoyuki Taniguchi (RIKEN Advanced Science Institute) and Drs. Takeo Ishii and Kozui Kida (Respiratory Care Clinic, Nippon Medical School) hypothesized that the presence of Siglec-14 may influence the frequency of exacerbation episodes in COPD patients.

The team analyzed the correlation between the genotype of SIGLEC14 gene and the frequency of COPD during 1 year of monitoring in 135 COPD patients, and found that those patients who do not have Siglec-14 (31 patients) suffer far fewer episodes of exacerbations (nearly 80% less) on average compared with those who do (104 patients).

These findings by the team suggest that COPD may be stratified based on the SIGLEC14 genotype for more efficient and personalized care. They also imply that Siglec-14 protein is involved in the exacerbation of COPD, and that a compound that blocks the inflammatory events triggered by Siglec-14 engagement could be used to prevent or treat the exacerbation of COPD.

More information: Takashi Angata, Takeo Ishii, Takashi Motegi, Ritsuko Oka, Rachel E. Taylor, Paula Campos Soto, Yung-Chi Chang, Ismael Secundino, Cong-Xiao Gao, Kazuaki Ohtsubo, Shinobu Kitazume, Victor Nizet, Ajit Varki, Akihiko Gemma, Kozui Kida, and Naoyuki Taniguchi. "Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation". Cellular and Molecular Life Sciences, 2013, doi: 10.1007/s00018-013-1311-7

add to favorites email to friend print save as pdf

Related Stories

COPD patients often given wrong treatment

Apr 21, 2009

(PhysOrg.com) -- Generally speaking, patients with COPD (Chronic Obstructive Pulmonary Disease) deteriorate suddenly, in bursts, often as a result of bacterial or viral infections.

Recommended for you

Restrictions lifted at British bird flu farm

14 hours ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

Dec 20, 2014

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.